馃攳
5 high growth stocks trading close to their 52 week low - YouTube
Channel: Groww
[8]
Hello! The 52-week high or low is a technical indicator that becomes an important factor for traders and investors in predicting the future price movement of any stock.
[18]
Especially if we talk about the 52-week low, there are many investors who like to buy undervalued stocks
[25]
That's why today we bring you 5 such high-growth companies that are trading near their 52-week lows.
[32]
Generally, a stock's 52W high is considered a resistance level and similarly, a 52W low is considered a support level. But it can also prove to be tricky.
[41]
There is no guarantee that a stock that is trading near its 52-week low will not go below that.
[48]
So you should not invest in any stock only on the basis that it is trading close to its 52W high or low.
[56]
For today's video, we have considered those stocks whose:
[72]
The numbers in the video that we have considered are at market closing on August 08, 2022.
[78]
The company whose stock is closest to its 52-week low, we'll cover at the end. So let's start today's list.
[95]
The first company is Intellect Design Arena Limited.
[97]
Intellect Design Arena Limited is involved in the business of providing technology in the fields of Banking, Financial Services, and Insurance.
[104]
The company's cash management products such as CashNow, Cash Extra, and CashPower are tailor-made for small, medium, and large enterprises.
[113]
These can give the company a good scope to expand beyond banking, financial services, and insurance in the times to come.
[120]
The stock is trading 9.35% above its 52-week low.
[125]
One of the strengths of the company is its diversified revenue. The revenue concentration of most companies in this sector is very high.
[132]
But the company has 270+ global customers distributed in 97+ countries.
[138]
Most of the company's revenues come from developed markets such as the USA, UK, Canada, and the EU.
[144]
Apart from this, markets like India have also contributed very well to the revenue growth of the company.
[150]
This type of diversification helps the company immensely in times of global uncertainties.
[154]
A significant risk aspect for the company is regulatory changes in the banking and financial sector.
[160]
This sector is heavily regulated worldwide and that too from time to time. So, the company has to pay a lot of attention to the rules of the history of each country.
[170]
It also has a few central banks in its client base. And the rules in the BFSI sector can change anytime according to the needs of the authorities and the economy.
[181]
Now you can see the key financial and technical ratios of the company on the screen.
[186]
We have also included the prices of 2 technical indicators so that you can see the stocks from a technical perspective as well.
[192]
We have used 2 indicators- 200 days simple moving average i.e. 200 days SMA and RSI (14).
[198]
If a company's stock price is trading above the 200 DMA, the stock can be considered bullish.
[204]
And if the price is trading below compared to the 200 DMA then the stock can be said to be bearish.
[210]
Talking about the RSI, an RSI value below 30 is generally considered oversold, and a trend reversal is likely to lead to an uptrend.
[220]
Similarly, an RSI value above 70 is considered overbought, and a trend reversal is likely.
[228]
The second company that we will talk about is Mastek Ltd.
[232]
Mastek Ltd India is a leading vertically-focused enterprise technology solutions provider.
[237]
After nearly 4 decades in the IT industry, the company has evolved itself from an IT solutions provider to a digital transformation partner.
[246]
The company mainly provides services like Application Development, Application Maintenance and Support, ERP and Cloud Migration, Business Intelligence, and Analytics.
[256]
The stock is 9.11% above its 52-week low.
[261]
The company's recent acquisition, Evosys, has helped them provide end-to-end solutions that have helped improve their margins from 14% to 21%.
[271]
With such acquisitions, it aspires is determined to achieve the target of US $ 1 billion revenue in the next 5-6 years.
[279]
New acquisitions, increasing deal size, expanding sales and marketing and gains in UK market share are all playing a big role in the company's revenue growth.
[288]
Also, the company is looking to scale up its business to reduce geographic risk.
[294]
Mastek had reported a weak quarter in Q1 FY23 with lower-than-expected revenue and margin performance.
[301]
The company's revenue was down 1.9% QoQ mainly due to NHS, UK account.
[307]
Their major software program was put on hold due to political uncertainty and the ongoing organizational restructuring in the NHS, UK.
[315]
While the UK government's technology spending has been slowing down over the last few quarters, so, the company might face difficulties cracking new deals in the near term.
[326]
As you can see on your screen, we have shown some key financial and technical ratios of the company.
[333]
The third company is Gland Pharma Limited.
[335]
Gland Pharma started its journey with contract manufacturing of a few products.
[339]
Today, Gland Pharma is one of India's largest and fastest-growing injectable-focused companies.
[345]
The company's footprint includes markets like the USA, Europe, Canada, Australia, and India in 60 countries.
[352]
The stock is 6.81% above its 52-week low.
[357]
The company's R&D expenditure in the quarter stood at around Rs 41 crore, which accounts for 4.8% of the total sales.
[364]
The company has 1,557 products registered globally. The company has filed a summary of new drug applications for 6 ANDAs this quarter.
[374]
As of June 2022, the company has approximately 316 ANDA filings in the US.
[380]
One worrying fact for the company is the Financial Results of the company for quarter 1 of FY23.
[385]
The company's revenue declined by 26% in the year which is one of the sharpest declines for the company. The company's revenue declined across geographies.
[395]
The company's revenue in India has declined by 72% on a year-to-year basis.
[399]
Let us now look at the company's financial and technical ratios.
[408]
The fourth company on our list is GAIL India Limited.
[411]
GAIL India is an integrated Natural Gas PSU Company. It owns 11,500 km of natural gas pipeline, 2,300 km of LPG pipeline, 6 LPG gas processing units, and a petrochemical facility in India.
[424]
The company has a presence in many cities as City Gas Distribution. The stock is 6.51% above its 52-week low.
[432]
The company has leadership in natural gas transmission. GAIL enjoys a dominant position in this space with a 70% market share and a pipeline network of 13,350 km.
[443]
Setting up pipelines requires a lot of investment and regulatory clearance given the high entry barriers in the sector.
[451]
Because of this, GAIL has the power to convert the favorable energy policies of the government into a good opportunity in the times to come.
[458]
In Dec 2011, it signed an agreement with Chenier Energy's Sabine Pass liquefaction plant and Cove Point terminal plants in the US to import 5.8 MMTPA of LNG from Cool Mill.
[471]
The pricing formula for these contracts is linked to the HH-index, which is the benchmark index for natural gas in the US.
[478]
HH-linked contracts keep GAIL constantly exposed to price risk, especially in these volatile times.
[484]
Now you can see the key financial and technical ratios of the company on the screen.
[491]
The last company is Alkem Laboratories Ltd.
[493]
It is involved in the development, manufacturing, and selling of pharmaceutical and nutraceutical products.
[499]
Its portfolio includes well-known brands such as Clavam, Pan, Pan-D, and Taxim-O. These brands feature in the top 50 pharma brands in India.
[508]
The company has 20 manufacturing plants in different locations in India and the United States.
[513]
The stock is 5.53% above its 52-week low.
[518]
It is continuously launching new products in chronic portfolio in rapidly growing segments- central nervous system, cardiac, and anti-diabetes, investing heavily in its marketing to scale-up brands.
[532]
However, in the long term, these initiatives will increase the company's profit margins, but their implementation will take time.
[539]
Also, due to significant pricing pressure in the US generic pharma market, the company's revenue declined 8% year-on-year in the last quarter.
[549]
Its direct impact has also been seen in the results of the company.
[552]
In Q1FY23 for the company in foreign exchange, approximately Rs. 500 million was lost due to which their margins were also hit.
[561]
Experts say that due to the slowdown in the US, this trend may continue in the coming one or two quarters.
[567]
Let us now look at the company's financial and technical ratios.
[573]
So these are the 5 high-growth companies that are trading in your 52-week view.
[577]
We remind you that this video is for educational purposes only, and is not a buy or sell recommendation of any kind.
[583]
We have launched our new channel, Trading with Groww where we explain trading concepts like charts, indicators, future, options, etc in a simple way to our viewers.
[594]
You may also join it. The channel link is in the description.
[598]
Don't forget to subscribe to the Groww channel for the latest updates about the market. Bye
Most Recent Videos:
You can go back to the homepage right here: Homepage





